The prognostic value of biomarkers after a premature myocardial infarction

被引:21
作者
Pineda, Javier [1 ]
Marin, Francisco [1 ,4 ]
Marco, Pascual [2 ]
Roldan, Vanessa [3 ]
Valencia, Jose [1 ]
Miguel Ruiz-Nodar, Juan [1 ]
Hernandez Romero, Diana [4 ]
Sogorb, Francisco [1 ]
Lip, Gregory Y. H. [5 ]
机构
[1] Hosp Gen Univ Alicante, Dept Cardiol, Alicante 03010, Spain
[2] Hosp Gen Univ Alicante, Dept Haematol, Alicante 03010, Spain
[3] Hosp Morales Meseguer, Dept Haematol, Murcia, Spain
[4] Hosp Univ Virgen Arrixaca, Dept Cardiol, Murcia, Spain
[5] City Hosp, Univ Dept Med, Birmingham, W Midlands, England
关键词
Young myocardial infarction; Prognostic markers; Coronary risk factors; C-REACTIVE PROTEIN; CORONARY-ARTERY-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; VON-WILLEBRAND-FACTOR; RISK-FACTORS; HEART-DISEASE; ANTIPHOSPHOLIPID ANTIBODIES; ANTICARDIOLIPIN ANTIBODIES; CARDIOVASCULAR-DISEASE; SMOKING-CESSATION;
D O I
10.1016/j.ijcard.2009.02.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Intravascular thrombogenesis is influenced by a complex interplay of factors related to a procoagulant state, fibrinolysis, endothelial damage/dysfunction and inflammation. We hypothesised that abnormalities of these biological systems would contribute to outcome of coronary artery disease presenting at a young age. Methods: We performed a prospective study of 142 subjects presenting with acute myocardial infarction (AMI) at a young age (defined as age <= 45 years), to determine the clinical and laboratory predictors of cardiovascular events during 36 months of follow-up. We assessed conventional risk factors and abnormalities of thrombophilia [total homocysteine (tHcy), lipoprotein (a) [Lp(a)], antiphospholipid antibodies (APA)], as well as lipid profile (total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides), fibrinogen and fibrin D-dimer (as indices of a hypercoagulable state and thrombogenesis), von Willebrand factor (vWF, an index of endothelial damage/dysfunction), tissue plasminogen activator [t-PA antigen] and its inhibitor [PAI-1 antigen] (as indices of fibrinolysis), and C-reactive protein [CRP] (an index of inflammation). Results: In a multivariate analysis, the variables independently associated with cardiovascular events at follow-up were levels of homocysteine (OR 3.73, 95% CI (1.54-9.02); p= 0.003), left ventricle systolic dysfunction (OR 3.04, 95% CI (1.00-9.25); p= 0.050), and smoking habit (OR 2.79, 95% CI (1.09-7.14) p= 0.032). Conclusions: Prognostic markers associated with cardiovascular events in premature CAD (young AMI subjects) were cigarette smoking and EF<50% of left ventricle as conventional clinical risk factors, as well as higher levels of homocysteine. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:249 / 254
页数:6
相关论文
共 55 条
[1]   Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study [J].
Albert, MA ;
Danielson, E ;
Rifai, N ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01) :64-70
[2]   Myocardial infarction redefined -: A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction [J].
Alpert, JS ;
Antman, E ;
Apple, F ;
Armstrong, PW ;
Bassand, JP ;
de Luna, AB ;
Beller, G ;
Breithardt, G ;
Chaitman, BR ;
Clemmensen, P ;
Falk, E ;
Fishbein, MC ;
Galvani, M ;
Garson, A ;
Grines, C ;
Hamm, C ;
Hoppe, U ;
Jaffe, A ;
Katus, H ;
Kjekshus, J ;
Klein, W ;
Klootwijk, P ;
Lenfant, C ;
Levy, D ;
Levy, RI ;
Luepker, R ;
Marcus, F ;
Näslund, U ;
Ohman, M ;
Pahlm, O ;
Poole-Wilson, P ;
Popp, R ;
Pyörälä, K ;
Ravkilde, J ;
Rehnquist, N ;
Roberts, W ;
Roberts, R ;
Roelandt, J ;
Rydén, L ;
Sans, S ;
Simoons, ML ;
Thygesen, K ;
Tunstall-Pedoe, H ;
Underwood, R ;
Uretsky, BF ;
de Werf, FV ;
Voipio-Pulkki, LM ;
Wagner, G ;
Wallentin, L ;
Wijns, W .
EUROPEAN HEART JOURNAL, 2000, 21 (18) :1502-1513
[3]   Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease [J].
Anderson, JL ;
Muhlestein, JB ;
Horne, BD ;
Carlquist, JF ;
Bair, TL ;
Madsen, TE ;
Pearson, RR .
CIRCULATION, 2000, 102 (11) :1227-1232
[4]  
[Anonymous], 1979, Circulation, V59, P607
[5]   CORONARY-THROMBOSIS IN NONCARDIAC DEATH [J].
ARBUSTINI, E ;
GRASSO, M ;
DIEGOLI, M ;
MORBINI, P ;
AGUZZI, A ;
FASANI, R ;
SPECCHIA, G .
CORONARY ARTERY DISEASE, 1993, 4 (09) :751-759
[6]  
ASHERSON RA, 1989, Q J MED, V73, P1103
[7]   High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions [J].
Barter, P ;
Kastelein, J ;
Nunn, A ;
Hobbs, R .
ATHEROSCLEROSIS, 2003, 168 (02) :195-211
[8]   Diabetes and atherosclerosis - Epidemiology, pathophysiology, and management [J].
Beckman, JA ;
Creager, MA ;
Libby, P .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (19) :2570-2581
[9]   EFFECTS OF SMOKING ON SURVIVAL AND MORBIDITY IN PATIENTS RANDOMIZED TO MEDICAL OR SURGICAL THERAPY IN THE CORONARY-ARTERY SURGERY STUDY (CASS) - 10-YEAR FOLLOW-UP [J].
CAVENDER, JB ;
ROGERS, WJ ;
FISHER, LD ;
GERSH, BJ ;
COGGIN, CJ ;
MYERS, WO .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 20 (02) :287-294
[10]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252